运动减轻了肝脏衰老,但在与肥胖相关的MASLD中没有超过饮食限制
Angeliki Katsarou1, Grigorios Papadopoulos1, Ioannis I Moustakas1
1Department of Physiology, Medical School, National and Kapodistrian University of Athens, 11527 Athens, Greece.
Metabolism: clinical and experimental
|June 12, 2025
概括
饮食限制和运动干预可以减少肝脏衰老和与代谢功能障碍相关的脂肪性肝病 (MASLD) 的特征. 将饮食限制与运动 (DREX) 结合起来,对MASLD显示出比单独运动更强大的益处.
科学领域:
- 肝病学 肝病学是一种肝病学.
- 细胞衰老 细胞衰老
- 代谢性疾病是代谢性疾病.
背景情况:
- 肝脏衰老是代谢功能障碍相关的脂肪性肝病 (MASLD) 的关键因素.
- 了解肝脏衰老的干预措施对于管理MASLD至关重要.
研究的目的:
- 调查有氧运动和饮食限制对MASLD肝脏衰老的影响.
- 为了比较这些干预措施的个人和综合效益.
主要方法:
- 给小鼠提供正常饮食 (ND) 或高脂肪饮食 (HFD) 和高果糖玉米糖 (HFCS).
- 干预措施包括饮食限制 (DR),有氧运动 (EX) 或组合 (DREX).
- 分析了衰老生物标志物 (mRNA,GL13,p21 WAF1/CIP1,p16INK4A) 和肝硬化/纤维化.
主要成果:
- 与单独使用EX相比,DR和DREX干预显著降低了肥胖,肝硬化和纤维化.
- p21 WAF1/CIP1 mRNA在HFD肝脏中增加,但通过包括DR的干预措施逆转.
- p16INK4A在HFD肝脏中增加,并被DR/DREX逆转,证实了组织变化.
结论:
- 肝脏衰老对运动和饮食限制都有反应.
- 包括DR的干预措施在MASLD中提供了更强大的肝衰老改善.
更多相关视频
06:28A Chronic High-Intensity Interval Training and Diet-Induced Obesity Model to Maximize Exercise Effort and Induce Physiologic Changes in Rats
Published on: April 28, 2023
808
07:03Author Spotlight: Establishing MASLD Cell Models for Investigating Disease Mechanisms and the Lipid-Lowering Effects of Koumiss
Published on: July 19, 2024
828
相关概念视频
Liver Regeneration
The liver is an important organ in vertebrates that plays an essential role in metabolism. It is also responsible for storing and redistributing nutrients such as carbohydrates, fats, and vitamins in the body. Additionally, the liver releases bile salts which are critical for digesting food and eliminating toxic metabolites from the body.
Cells of Liver
The liver comprises four major types of cells— hepatocytes, stellate, Kupffer, and sinusoidal endothelial cells. The hepatocytes are large...
Cells of Liver
The liver comprises four major types of cells— hepatocytes, stellate, Kupffer, and sinusoidal endothelial cells. The hepatocytes are large...
Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion
Drug metabolism, a critical process in the liver, involves two primary phases: Phase I reactions and Phase II conjugation. Obesity introduces significant alterations in this metabolic process, primarily due to fatty infiltration of the liver, leading to conditions such as nonalcoholic fatty liver disease (NAFLD). This condition can modify the activities of both Phase I and II enzymes, impacting how drugs are metabolized in obese patients.Phase I metabolism sees variable effects across...
Atherosclerosis III: Management
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
